Ben Chien

Biography

 Ben is Founder, Chairman of Foresee Pharmaceuticals. Foresee was founded as a research division of QPS and spun-off in 2011. Ben founded QPS in 1995 and now employs more than 1170 people at 9 facilities in the Delaware (US), Missouri (US), Florida (US), North Caroline (US), North Dakota (US), Groningen (The Netherlands), Graz (Austria), Hyderabad (India), and Taipei (Taiwan). QPS is the recipient of “2013 Company of the Year Award” by Delaware Bioscience Association. “CEO of 2015 Award” by Finance Monthly. Ben also co-founded Theracore Pharmaceuticals, Inc. in 2003. Its radiopharmaceutical division was subsequently spun-off to form Avid Radiopharmaceuticals, Inc. in 2005. Avid was acquired by Eli Lilly in late 2010 for $880 million. Its leading imaging agent Amyvid was approved in April, 2012. Ben obtained his Ph.D. in analytical chemistry (mass spectrometry) from the University of Michigan at Ann Arbor with Prof. David M. Lubman. Ben is the co-inventor of a novel Ion Trap/Time-of-Flight Mass Spectrometer. The publication of this work was selected as “Best Student Paper of 1994”, awarded by International Journal of Mass Spectrometry and Ion Physics. Ben began his pharmaceutical career at DuPont Merck Pharmaceutical Co. in the Drug Metabolism and Pharmacokinetics Section, where he built the LC/MS/MS group dedicated to supporting drug discovery, preclinical and clinical studies. In 1996, Ben received the Summit Award, the highest level of achievement at DuPont Merck for his dedicated contribution to the development of Efavirenz, an anti-viral drug approved by the FDA for the treatment of HIV disease

Research Interest

 Ben is Founder, Chairman of Foresee Pharmaceuticals. Foresee was founded as a research division of QPS and spun-off in 2011. Ben founded QPS in 1995 and now employs more than 1170 people at 9 facilities in the Delaware (US), Missouri (US), Florida (US), North Caroline (US), North Dakota (US), Groningen (The Netherlands), Graz (Austria), Hyderabad (India), and Taipei (Taiwan). QPS is the recipient of “2013 Company of the Year Award” by Delaware Bioscience Association. “CEO of 2015 Award” by Finance Monthly. Ben also co-founded Theracore Pharmaceuticals, Inc. in 2003. Its radiopharmaceutical division was subsequently spun-off to form Avid Radiopharmaceuticals, Inc. in 2005. Avid was acquired by Eli Lilly in late 2010 for $880 million. Its leading imaging agent Amyvid was approved in April, 2012. Ben obtained his Ph.D. in analytical chemistry (mass spectrometry) from the University of Michigan at Ann Arbor with Prof. David M. Lubman. Ben is the co-inventor of a novel Ion Trap/Time-of-Flight Mass Spectrometer. The publication of this work was selected as “Best Student Paper of 1994”, awarded by International Journal of Mass Spectrometry and Ion Physics. Ben began his pharmaceutical career at DuPont Merck Pharmaceutical Co. in the Drug Metabolism and Pharmacokinetics Section, where he built the LC/MS/MS group dedicated to supporting drug discovery, preclinical and clinical studies. In 1996, Ben received the Summit Award, the highest level of achievement at DuPont Merck for his dedicated contribution to the development of Efavirenz, an anti-viral drug approved by the FDA for the treatment of HIV disease